Compare OSK & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSK | NUVL |
|---|---|---|
| Founded | 1917 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8B | 8.3B |
| IPO Year | 2009 | 2021 |
| Metric | OSK | NUVL |
|---|---|---|
| Price | $152.96 | $101.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 16 |
| Target Price | ★ $166.79 | $134.75 |
| AVG Volume (30 Days) | 463.4K | ★ 472.5K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.55% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $7,705,500,000.00 | N/A |
| Revenue This Year | $5.94 | N/A |
| Revenue Next Year | $7.19 | $1,239.49 |
| P/E Ratio | $137.37 | ★ N/A |
| Revenue Growth | ★ 12.83 | N/A |
| 52 Week Low | $90.74 | $69.85 |
| 52 Week High | $180.49 | $113.02 |
| Indicator | OSK | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 52.45 | 47.50 |
| Support Level | $137.24 | $97.94 |
| Resistance Level | $158.57 | $107.49 |
| Average True Range (ATR) | 5.20 | 3.67 |
| MACD | 0.66 | -0.41 |
| Stochastic Oscillator | 57.24 | 33.33 |
Oshkosh is a leading maker of access equipment, specialty vehicles, and military trucks. It serves diverse end markets, including postal, firefighting, refuse/recycling collection, aviation, and construction. It is typically the market share leader or No. 2 player in North America, or even the global leader in the case of its JLG aerial work platform business. The transport segment is a leading provider of light trucks to the military and vehicles to the Postal Service. The vocational segment, featuring brands such as Pierce, AeroTech, and Volterra, offers purpose-built vehicles and equipment to municipalities. The company reports three segments—Access equipment (45% of revenue), Vocational (35%), and Transport (20%) on 2025 revenue of $10.4 billion.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.